PSA Screenings for Prostate Cancer Continue in US Despite Task Force’s Opposition

PSA Screenings for Prostate Cancer Continue in US Despite Task Force’s Opposition
Although the U.S. Preventive Services Task Force advised against prostate-specific antigen (PSA) screening for prostate cancer in 2012, arguing it led to excessive treatment, no significant reduction in the use of these tests is evident, according to a study of PSA practices at a major medical center in the years just before and after the recommendation was announced. The study, “Testing and referral

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Chris O'Neill says:

    “despite a 39 percent drop in prostate cancer mortality since that time, the potential for overtreatment has concerned clinicians, Lotan said.”

    It is misleading to just point out the observation of a drop in mortality over a particular period since there are many other changing variables in that period that could have had an effect on mortality.

    The actual reason for concern about over treatment is that randomised controlled trials (which reduce the impact of confounding variables) have failed to show any significant improvement in overall survival from increases in PSA screening and consequent increases in treatment.

Leave a Comment

Your email address will not be published. Required fields are marked *